125 related articles for article (PubMed ID: 30837393)
1. [Nivolumab-induced hypothyroidism: A case report].
Lin C; Guo Z; Mo Z
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2019 Feb; 44(2):222-224. PubMed ID: 30837393
[TBL] [Abstract][Full Text] [Related]
2. RAPID EVOLUTION OF THYROID DYSFUNCTION IN PATIENTS TREATED WITH NIVOLUMAB.
O'Malley G; Lee HJ; Parekh S; Galsky MD; Smith CB; Friedlander P; Yanagisawa RT; Gallagher EJ
Endocr Pract; 2017 Oct; 23(10):1223-1231. PubMed ID: 29045188
[TBL] [Abstract][Full Text] [Related]
3. So slow, so fast, a case of nivolumab-induced hypothyroidism with subsequent rhabdomyolysis.
Abushalha K; Abulaimoun S; Silberstein PT
Immunotherapy; 2020 Jun; 12(9):625-628. PubMed ID: 32418490
[No Abstract] [Full Text] [Related]
4. Nivolumab-induced thyroid dysfunction.
Tanaka R; Fujisawa Y; Maruyama H; Nakamura Y; Yoshino K; Ohtsuka M; Fujimoto M
Jpn J Clin Oncol; 2016 Jun; 46(6):575-9. PubMed ID: 27012985
[TBL] [Abstract][Full Text] [Related]
5. Immunoassay Interference on Thyroid Function Tests During Treatment with Nivolumab.
Paragliola RM; Corsello A; Papi G; Melfa E; Urbani A; Pontecorvi A; Corsello SM; Carrozza C
Thyroid; 2020 Jul; 30(7):1091-1094. PubMed ID: 32122271
[No Abstract] [Full Text] [Related]
6. Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study.
Yamauchi I; Sakane Y; Fukuda Y; Fujii T; Taura D; Hirata M; Hirota K; Ueda Y; Kanai Y; Yamashita Y; Kondo E; Sone M; Yasoda A; Inagaki N
Thyroid; 2017 Jul; 27(7):894-901. PubMed ID: 28537531
[TBL] [Abstract][Full Text] [Related]
7. Primary hypothyroidism and isolated ACTH deficiency induced by nivolumab therapy: Case report and review.
Zeng MF; Chen LL; Ye HY; Gong W; Zhou LN; Li YM; Zhao XL
Medicine (Baltimore); 2017 Nov; 96(44):e8426. PubMed ID: 29095280
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab-induced hypothyoidism with consequent hypothyroid related myopathy.
Johnson ED; Kerrigan K; Butler K; Patel SB
J Oncol Pharm Pract; 2020 Jan; 26(1):224-227. PubMed ID: 30880569
[TBL] [Abstract][Full Text] [Related]
9. Painless Thyroiditis and Fulminant Type 1 Diabetes Mellitus in a Patient Treated with an Immune Checkpoint Inhibitor, Nivolumab.
Sakurai K; Niitsuma S; Sato R; Takahashi K; Arihara Z
Tohoku J Exp Med; 2018 Jan; 244(1):33-40. PubMed ID: 29343652
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab induced myxedema crisis.
Khan U; Rizvi H; Sano D; Chiu J; Hadid T
J Immunother Cancer; 2017; 5():13. PubMed ID: 28239466
[TBL] [Abstract][Full Text] [Related]
11. Anti-programmed death-1 inhibitor nivolumab-induced immune-related adverse events: hepatitis, renal insufficiency, myositis, vitiligo, and hypothyroidism: a case-based review.
Zekić T; Benić MS
Rheumatol Int; 2023 Mar; 43(3):559-565. PubMed ID: 36449057
[TBL] [Abstract][Full Text] [Related]
12. [Varied immuno-related adverse events induced by immune-check point inhibitors - Nivolumab-associated psoriasiform dermatitis related with increased serum level of interleukin-6].
Okiyama N; Tanaka R
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(2):95-101. PubMed ID: 28603207
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab-induced synchronous occurrence of myositis and hypothyroidism in a patient with squamous cell lung cancer.
Badovinac S; Korsic M; Zarkovic K; Mursic D; Roglic M; Jakopovic M; Samarzija M
Immunotherapy; 2018 Mar; 10(6):427-431. PubMed ID: 29562858
[TBL] [Abstract][Full Text] [Related]
14. Immune-mediated thrombocytopenia and hypothyroidism in a lung cancer patient treated with nivolumab.
Jotatsu T; Oda K; Yamaguchi Y; Noguchi S; Kawanami T; Kido T; Satoh M; Yatera K
Immunotherapy; 2018 Feb; 10(2):85-91. PubMed ID: 29260625
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab-induced hypothyroidism followed by isolated ACTH deficiency.
Martins Machado C; Almeida Santos L; Barroso A; Oliveira MJ
BMJ Case Rep; 2019 Aug; 12(8):. PubMed ID: 31466960
[TBL] [Abstract][Full Text] [Related]
16. [Effectiveness of a Low-dose Corticosteroid in a Patient with Polymyalgia Rheumatica Associated with Nivolumab Treatment].
Imai Y; Tanaka M; Fujii R; Uchitani K; Okazaki K
Yakugaku Zasshi; 2019; 139(3):491-495. PubMed ID: 30828027
[TBL] [Abstract][Full Text] [Related]
17. [Clinical observation of thyroid-related adverse events induced by anti-PD-1 antibody SHR-1210 in patients with advanced solid tumor].
Qi L; Mo HN; Chen XL; Wang X; Wu DW; Lan B; Li Q; Wang XY; Xu JP; Yang Q; Xu BH; Huang J
Zhonghua Zhong Liu Za Zhi; 2018 Oct; 40(10):772-775. PubMed ID: 30392342
[No Abstract] [Full Text] [Related]
18. Nivolumab-induced thyroid dysfunction lacking antithyroid antibody is frequently evoked in Japanese patients with malignant melanoma.
Yano S; Ashida K; Nagata H; Ohe K; Wada N; Takeichi Y; Hanada Y; Ibayashi Y; Wang L; Sakamoto S; Sakamoto R; Uchi H; Shiratsuchi M; Furue M; Nomura M; Ogawa Y
BMC Endocr Disord; 2018 Jun; 18(1):36. PubMed ID: 29884162
[TBL] [Abstract][Full Text] [Related]
19. [Initially undetected de novo psoriasis triggered by nivolumab for metastatic base of the tongue carcinoma].
Troyanova-Slavkova S; Eickenscheidt L; Dumann K; Kowalzick L
Hautarzt; 2018 Aug; 69(8):674-680. PubMed ID: 29330579
[TBL] [Abstract][Full Text] [Related]
20. Mitotane treatment in patients with adrenocortical cancer causes central hypothyroidism.
Russo M; Scollo C; Pellegriti G; Cotta OR; Squatrito S; Frasca F; Cannavò S; Gullo D
Clin Endocrinol (Oxf); 2016 Apr; 84(4):614-9. PubMed ID: 26221968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
